August 14, 2025
2 min watch
Key takeaways:
- Gildeuretinol helped sufferers keep visible acuity for as much as 7 years.
- The oral remedy was properly tolerated.
LONG BEACH, Calif. — Oral gildeuretinol helped sufferers with Stargardt illness keep visible acuity for as much as 7 years of therapy, in keeping with a research.
Kenneth Fan, MD, MBA, mentioned interim knowledge from the TEASE-3 research on the American Society of Retina Specialists annual assembly.
“What we offered was primarily knowledge gildeuretinol, which is an investigational therapy for Stargardt illness, which reduces vitamin A dimerization and due to this fact reduces A2E and lipofuscin accumulation in photoreceptors and [retinal pigment epithelium],” Fan advised Healio. “It does this by changing a hydrogen with a deuterium molecule at carbon 20. It makes it heavier and more durable to cleave.”
The TEASE-3 research is an open-label 24-month research evaluating gildeuretinol (Alkeus Prescribed drugs) in sufferers aged 8 to 70 years outdated with genetic-confirmed Stargardt illness and early indicators of maculopathy on fundus autofluorescence or OCT with out well-delineated atrophic lesions. The research is ongoing and has a goal enrollment of 20 sufferers.
Fan offered knowledge from six sufferers with a median age of 14 years and a median greatest corrected visible acuity of 20/20. He stated sufferers who acquired gildeuretinol had steady visible acuity for as much as 7 years of therapy. The remedy was properly tolerated, with one treatment-emergent severe antagonistic occasion not associated to the research drug.
The research additionally checked out ellipsoid zone space progress over time in contrast with sibling knowledge. Fan stated brothers and sisters who had historic imaging however didn’t endure therapy with gildeuretinol confirmed a better price of ellipsoid zone space progress in contrast with these handled within the research.
“Total, that is actually nice knowledge demonstrating the protection and efficacy of gildeuretinol in early Stargardt illness,” Fan advised Healio.
Sources/Disclosures
Collapse
Fan Ok, et al. Oral gildeuretinol slows illness development in early Stargardt illness: Updates from the TEASE-3 research. Introduced at: American Society of Retina Specialists annual assembly; July 30-Aug. 2, 2025; Lengthy Seashore, California.
Disclosures:
Fan reviews serving on the advisory board for Alkeus Prescribed drugs.
